

# **Prenatal Therapy for Spinal Muscular Atrophy**

## Provided by

**Speaker:** Richard Finkel, MD

Date/Time: 1/12/2023 8:00:00 AM

Location: Marlo Thomas Center Auditorium

## **Educational Objectives**

At the conclusion of this activity, the participant will be able to:

1 Discuss gene-targeted treatments for rare diseases, using the example of spinal muscular atrophy (SMA)

2 Discuss the advances in treatment of patients with SMA

3 Understand fetal therapy for genetic disorders, using the example of a case with SMA treated at St. Jude

### **Credit Designation**

St. Jude Children's Research Hospital designates this live activity for a maximum of **1.00** AMA PRA Category 1 Credit(s) $^{TM}$ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### **Accreditation Statement**

St. Jude Children's Research Hospital is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

## Disclosure of Financial Relationships

The following speakers and other individuals in control of content have the following financial relationship(s) with commercial interests to disclose:

Richard Finkel, MD: Advisor-Biogen|Advisor-Sarepta|Advisor-Roche|Advisor-Novartis|Advisor-Scholar Rock|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Ionis Pharmaceuticals|Grant or research support-Genentech - 12/28/2022